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Abstract
Background
Injection drug use is a growing major public health concern. Injection drug users (IDUs)
have a higher incidence of co-morbidities including HIV, Hepatitis, and other infections. An
effective humoral response is critical for optimal homeostasis and protection from infection;
however, the impact of injection heroin use on humoral immunity is poorly understood. We
hypothesized that IDUs have altered B cell and antibody profiles.
Methods and Findings
A comprehensive systems biology-based cross-sectional assessment of 130 peripheral
blood B cell flow cytometry- and plasma- based features was performed on HIV-/Hepatitis
C-, active heroin IDUs who participated in a syringe exchange program (n = 19) and healthy
control subjects (n = 19). The IDU group had substantial polydrug use, with 89% reporting
cocaine injection within the preceding month. IDUs exhibited a significant, 2-fold increase in
total B cells compared to healthy subjects, which was associated with increased activated B
cell subsets. Although plasma total IgG titers were similar between groups, IDUs had signifi-
cantly higher IgG3 and IgG4, suggestive of chronic B cell activation. Total IgM was also
increased in IDUs, as well as HIV Envelope-specific IgM, suggestive of increased HIV expo-
sure. IDUs exhibited numerous features suggestive of systemic inflammation, including sig-
nificantly increased plasma sCD40L, TNF-α, TGF-α, IL-8, and ceramide metabolites.
Machine learning multivariate analysis distilled a set of 10 features that classified samples
based on group with absolute accuracy.
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Conclusions
These results demonstrate broad alterations in the steady-state humoral profile of IDUs that
are associated with increased systemic inflammation. Such dysregulation may impact the
ability of IDUs to generate optimal responses to vaccination and infection, or lead to
increased risk for inflammation-related co-morbidities, and should be considered when
developing immune-based interventions for this growing population.
Introduction
Injection drug use continues to be a major public health issue, with rapid growth in recent
years. The rate of heroin use and overdose doubled in the United States between 2010 and 2012
[1, 2]. Numerous co-morbidities are associated with injection drug use including increased risk
of cardiovascular disease, chronic kidney disease, gastrointestinal diseases, and infections [3–
5]. Along with HIV and Hepatitis C, which are primarily transmitted in IDUs through sharing
of contaminated needles, there is increased incidence of bacteremia [4] and soft-tissue injection
site infections that include Staphylococcus aureus, Group A streptococci, and Clostridial infec-
tions [6–8]. In addition to increased exposure to pathogens, prolonged injection drug use has
been associated with immune dysregulation that may diminish effective innate and adaptive
immune responses [9].
Opiates, including heroin, can directly act on immune cells through opioid receptors, and
result in decreased in vitro T cell proliferation and cytokine production [10], and decreased
phagocytosis and chemotaxis of macrophages [11]. In mice, morphine has been shown to
inhibit antibody responses [11–13]. Although heroin dominates illicit injection drug use, poly-
drug use is substantial among IDUs, including use of cocaine and methamphetamine [14, 15],
which prevents clear extrapolation of the impact of opiates on the immune system in animal
models to the complexity of IDUs, necessitating a direct and comprehensive assessment of the
injection drug user population.
Several studies have reported elevated inflammatory mediators associated with IDUs,
including serum IL-1β, IL-6, and IL-8 in methadone-maintained IDUs [16] [17], and increased
dendritic cell and natural killer cell activation in IDUs that is associated with needle sharing
[18]. These findings suggest that multiple mediators may be contributing to altered immune
homeostasis in IDUs. Direct assessment of immune responsiveness in IDUs has been limited,
although diminished antibody responses to vaccinations, including Hepatitis A and B have
been observed in IDUs [19, 20]. Studies thus far have primarily measured only serum IgG anti-
body, and have not evaluated potential qualitative differences among the serum antibody
response or direct evaluation of the B cells, which may influence vaccine efficacy, particularly
for HIV [21].
The primary objective of preventative vaccine strategies against HIV is the induction of a
persistent humoral response that mediates sterilizing immunity. Although modest, encourag-
ing results of a short-lived reduction in infections in low-risk individuals were obtained in the
RV144 HIV vaccine efficacy trial [22] for high-risk individuals, including IDUs, no substantial
reduction in infection has been observed in HIV vaccine efficacy trials [23–25]. Furthermore,
correlates of protection associated with RV144 included the IgG3 antibody response to a par-
ticular epitope (V1V2) on the HIV Envelope protein, and not the overall IgG antibody
response to the vaccine [26], highlighting the qualitative subtleties that may determine HIV
vaccine efficacy. Most mechanistic vaccine studies, including those for HIV vaccines, are
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primarily conducted with healthy subjects. This approach creates the vulnerability that
advances in vaccine efficacy realized in healthy subjects may be difficult to translate to the IDU
population, which is at high risk for HIV infection.
The impact of injection drug use on humoral responses is poorly defined. We sought to
identify potential differences in the humoral profile of IDUs that could impact their immune
responses and overall health. Through a cross-sectional assessment of peripheral blood B cells
and plasma analytes, we have identified substantial alterations in IDUs that are associated with
increased systemic inflammation, and which have the potential to influence the quality of the B
cell and antibody response to vaccinations, infections, and contribute to inflammation-associ-
ated co-morbidities.
Material and Methods
Clinical samples and questionnaire
Peripheral blood samples were obtained from active IDUs recruited through the Trillium
Health Syringe Exchange Program in Rochester, NY, during 2014. The IDUs were defined as
having injected heroin within the previous 3 days and having a history of at least weekly heroin
injection for a period of at least 3 months in duration within the previous 12 months. Healthy
controls (HCs) with no history of substance abuse, no use of opiates (prescription or non-pre-
scription), prescription stimulants, or illicit substances (excluding marijuana) within the previ-
ous 6 months were recruited at the University of Rochester Medical Center. All subjects were
at least 110 lbs, 18–35 years old, HIV negative and Hepatitis C negative, and no history of
immunization within the previous 2 weeks, as determined by self-report. All subjects provided
signed, written informed consent. Competence and understanding of the informed consent
was assessed throughout the process by study staff through a series of questions regarding
study participation. Study subjects answered a series of questions regarding their demograph-
ics, health, substance use, sexual practices, and perspectives on vaccine research using a
Research Electronic Data Capture (REDCap)–based questionnaire, hosted at the University of
Rochester [27]. Peripheral blood was coded to blind the samples and was collected using CPT
tubes (BD Biosciences, Franklin Lakes, NJ); peripheral blood mononuclear cells (PBMCs) and
plasma were isolated and cryopreserved in a blinded manner as previously described [28]
before subsequent analysis. All procedures and methods were approved by the University of
Rochester Research Subjects Review Board.
Flow cytometry
For B cell phenotypic analysis PBMCs were stained similar to as previously described [28, 29]
with anti-CD19-APC-Cy7 (SJ25C1, BD), anti-CD20-AlexaFluor 700 (2H7, Biolegend, San
Diego, CA), anti-CD3-PacificOrange (UCHT1, Invitrogen, Carlsbad, CA), anti-IgD-FITC (IA6-
2, BD), anti-IgG-APC (G18-145, BD), anti-IgM-PE-Cy5 (G20-127, BD), anti-CD27-Qdot655
(CLB-27/1, Invitrogen), anti-CD21-V450 (B-ly4, BD), anti-CD14-PerCP-Cy5.5 (M5E2, BD),
anti-CD138-biotin (B-A38, Abcam, Cambridge, MA), streptavidin Qdot800 (Invitrogen), anti-
CD4-Qdot705 (S3.5, Invitrogen), anti-CD38-Qdot605 (HIT2, Invitrogen), anti-CD95-PE-Cy7
(DX2, Biolegend), anti-CD24-PE-AlexaFluor610 (SN3, Invitrogen), anti-CD183-PE (1C6/
CXCR3, BD) and Live/Dead fixable aqua dead cell stain (Invitrogen). One-to-two million total
events per sample were collected on an LSRII instrument (BD Biosciences). Staining and analysis
performed in a blinded manner, linking sample with experimental group after gating was com-
pleted using FlowJo software (Treestar, Inc, Ashland, OR). Total PBMC were gated on lympho-
cytes using FSC and SSC. Live/Dead stain, anti-CD3, anti-CD4, and anti-CD14 were used to
exclude dead cells, T cells, and monocytes respectively.
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Plasma antibody ELISAs and LAL
For detection of plasma total IgG and IgG subclasses ELISA plates were coated overnight with
1 μg/ml anti-human IgG (Jackson ImmunoResearch, 709-006-149, West Grove, PA) in PBS,
blocked with 2% nonfat dry milk and 2% BSA in PBS for 1 h, then washed with 0.1% Tween 20
in PBS. Samples were serially diluted in triplicate in PBS containing 0.01% Tween 20 and 0.5%
BSA, and incubated for 1h. Plates were washed, and binding was detected using anti-human
IgG-HRP (Jackson), anti-human IgG1-HRP (Southern Biotech, 9052–05, Birmingham, AL),
anti-human IgG2-HRP (Southern Biotech, 9070–05), anti-human IgG3-HRP (9210–05), or
anti-human IgG4-HRP diluted 1:2000 in PBS with 0.1% Tween 20. Total plasma IgM and IgA
were detected using 1 μg/ml anti-human IgM (Jackson, 109-006-129) with 1:2000 anti-human
IgM-HRP (Jackson, 109-035-129), and 1 μg/ml anti-human IgA (Jackson, 109-005-011) with
1:2000 anti-human IgA-HRP (Jackson, 309-035-011). ELISA plates were coated with 0.5 μg/ml
Tetanus toxoid (Calbiochem, San Diego, CA), 10 μg/ml LPS (Sigma- St. Louis, MO Aldrich),
or 1 μg/ml Sm antigen (Arotec Diagnostics, Wellington, New Zealand) and detected with
1:2000 anti-human IgG-HRP to measure Tetanus toxoid, LPS, and Sm specific IgG plasma
antibody respectively. ELISA plates were coated with 1 μg/ml HIV SF162 gp140 protein or
1 μg/ml HIV p24 protein (NIH AIDS Reagent Repository) and detected with either anti-
human IgG-HRP or anti-human IgM-HRP to measure HIV-specific antibody. Anti-dsDNA
IgG ELISA was performed, testing samples in duplicate using a commercial kit according to
manufacturer's (Inova Diagnostics, Sand Diego, CA) recommendations. Plasma LPS was mea-
sured using the Kinetic-QCL chromogenic LAL assay (Lonza, Basel, Switzerland) according to
manufacturer’s instructions.
Plasma analyte multiplex assay
Each plasma sample was tested in duplicate in a blinded manner using 25 μl plasma plus the
addition of 5 μl of heteroblock (Omega Biologicals, Bozeman, MT) to minimize non-specific
interactions [30] with a MilliPlex Human Cytokine/Chemokine assay (Millipore, Billerica,
MA, MPXHCYTO60KPMX42) according to manufacturer’s instructions. Values that were
below limit of detection were adjusted to non-zero value (10, 1, 0.1, or 0.01) depending on
lower limit of detection for individual analyte to enable statistical analysis.
Ceramide profiling: Lipid extraction and LC/ESI/MS/MS analysis
Lipids were extracted from plasma using a modified Bligh and Dyer procedure as previously
described [31]. The organic layer containing a crude lipid extract was dried using a nitrogen
evaporator (Organomation Associates Inc., Berlin, MA, USA), and resuspended in pure metha-
nol. Ceramides were detected by multiple reaction monitoring using a liquid chromatography
coupled electrospray ionization tandem mass spectrometer (ESI/MS/MS) (API3000; AB Sciex
Inc., Thornhill, ON, Canada) operated in positive mode. LC and MS/MS parameters have been
previously described [32]. Slight differences in extraction efficiency and fluctuations in the effi-
ciency of mass detection were normalized using a ceramide C12:0 internal standard (Avanti
Polar Lipids, Alabaster, AL). Instrument efficiency was monitored daily, and at the end of the
study individual plasma extracts were re-analyzed if the internal standard deviated more than
30% from the overall median internal standard value. Ceramide concentrations were deter-
mined by fitting the identified ceramide species to standard curves based on acyl-chain length.
Ceramide standards C16:0, C18:0, C18:1 were purchased from Sigma. Ceramides C20:0, C24:0,
C24:1 were purchased from Avanti Polar Lipids (Alabaster, AL). Palmitoyl-lactosyl ceramide
C16:0-C16:0, stearoyl-lactosyl-ceramide C16:0-C18:0, lignoceryl-glucosyl-ceramide
C16:0-C24:0, lignoceryl-galactosyl-ceramide C16:0-C24:0, and stearoyl-galactosyl-ceramide-
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sulfate C18:1-C24:0 were purchased fromMatreya Inc. (Pleasant Gap, PA). Instrument control
and quantitation were performed using Analyst 1.4.2, and MultiQuant software (AB Sciex Inc.
Thornhill, Ontario, Canada).
Statistical analysis
Univariate analysis of individual features was performed by the two-tailed Mann-Whitney test
to compare groups using Prism 5.0 software (GraphPad Software, La Jolla, CA). No correction
for multiple outcomes was performed due to the limited sample size and exploratory nature of
the project. Heat maps, cluster analysis and principal component analysis were performed
using Matlab (the Mathworks Inc., Natick MA).
Furthermore, a supervised machine learning classifier with wrapper method [33, 34] called
support vector machine (SVM) recursive feature elimination [35, 36] was used to find small
subsets of features that together have good predictive power to classify IDUs. In the first itera-
tion, a SVM classifier was trained using the complete set of (216) features (S1 File). These fea-
tures were then ranked based on their relative classification power in terms of their absolute
weights. The feature with the smallest weight was removed iteratively, each time upon training
a new SVM classifier. The performance of the classifier in each run was measured through
10-fold cross validation. IDU-23 was excluded from the training process because of its extreme
outlier profile. IDU-27 was also excluded from the training process because of a missing “cell
count” value. When these two subjects were independently tested on final SVM (built on top
10 features), the SVM was able to classify both of them accurately.
Results
Injection drug user population
Young adult HIV negative and Hepatitis C negative active IDUs (n = 19) were recruited
through the local syringe exchange program. The majority of the IDU cohort was white (84%)
and male at birth (68%) and similar in composition to the group of healthy controls (HCs)
(Table 1). IDUs reported reduced self-perception of their overall health and satisfaction with
their lives. Sexual risk behaviors did not significantly differ from HCs including past diagnosis
of a sexually transmitted infection, number of sexual partners, or incidence of unprotected anal
or vaginal intercourse. HIV testing rates were slightly higher among IDUs, as reported testing
within the previous 6 months was 47% in IDUs vs 28% in HCs, and 68% in IDUs vs 50% in
HCs within the previous year; likely driven by point-of-care HIV testing offered at the syringe
exchange. Encouragingly, the majority (73%) of IDUs indicated they were agreeable to partici-
pating in a hypothetical future HIV vaccine trial, and participating in a hypothetical future
research study that requires 10 visits (74%).
All IDUs had injected heroin within the preceding 72 hours of participation, and 56%
reported to had used heroin every day for the preceding 3 months (Table 2). The combined
use of heroin and cocaine was predominant, with 89% of IDUs reporting having injected
cocaine within the preceding 30 days. Of the IDUs, 44% indicated they were intoxicated for
most of the day for at least the majority of the days within the preceding 90 days. Occasional
sharing of syringes in the last 30 days was reported by 20% of the IDUs, and the remainder
indicated they had not shared needles in the past 30 days.
Increased total B cells and B cell activation among IDUs
As B cells are critical for protective immunity we investigated the phenotypic profile of the
peripheral blood B cell compartment for altered homeostasis. There were no significant
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Table 1. Participant Characteristics.
Healthy Control Group
(n = 19)
Injection Drug User Group
(n = 19)
Age (yrs) 24.3 (18–35) 28.4 (21–35) p = 0.014
Female (at birth) 42% 32% p = 0.2425
Transgender 5% 5% p = 1
Black 11% 5% p = 0.1913
White 79% 84% p = 0.4667
Body mass index 29.4 (19–47) 26.1 (21–38) p = 0.1409
“I seem to get sick a little easier than other people” (1 = deﬁnitely true, 5 = deﬁnitely
false)
3.8 (3–5) 3.1 (2–5) p = 0.005
“In general how satisﬁed are you with your life?” (very dissatisﬁed to very satisﬁed,
% satisﬁed to very satisﬁed)
95% 26% p<0.0001
 $15,000 annual income 47% 74% p = 0.0002
College graduate 58% 11% p<0.0001
Men who have sex with men (of males) 50% 8% p<0.0001
# of sexual partners in last 6 months 3.2 (0–30) 3.7 (0–42) p = 0.8603
Unprotected anal sex in last 6 months (not with main partner) 5% 5% p = 1
Sex for money, drugs, gifts, or services 5% 5% p = 1
New STI in last 6 months 5% 0% p = 0.0594
Ever diagnosed with STI 21% 26% P = 0.5050
HIV test w/in last 3 months 17% 37% p = 0.0023
HIV test w/in last 6 months 28% 47% p = 0.0084
HIV test w/in last year 50% 68% p = 0.0143
Willing to participate in future HIV vaccine trial: agree or strongly agree 68% 73% p = 0.5353
Willing to participate in a future research study that requires 1 visit: agree or strongly
agree
100% 84% p<0.0001
Willing to participate in a future research study that requires 10 visits: agree or
strongly agree
63% 74% p = 0.128
doi:10.1371/journal.pone.0158641.t001
Table 2. Substance Use Characteristics.
Healthy Control Group (n = 19) Injection Drug User Group (n = 19)
Tobacco use (any in last year) 24% 74% p< 0.001
Alcohol (at least 15 out of last 90 days) 16% 21% p = 0.467
Marijuana (at least 15 out of last 90 days) 0% 37% p< 0.001
Drunk or high most of the day (at least 1 day out of last 90 days) 21% 78% p< 0.001
Drunk or high most of the day (at least 16 out of last 90 days) 0% 61% p< 0.001
Drunk or high most of the day (at least 46 out of last 90 days) 0% 44% p< 0.001
Crack cocaine (at least 16 out of last 90 days) NA 26%
Non-crack cocaine (at least 16 out of last 90 days) NA 56%
Heroin (at least 16 out of last 90 days) NA 100%
Heroin (everyday of last 90 days) NA 56%
Injected cocaine (at least once in last 30 days) NA 89%
Most recent injection was both heroin and cocaine NA 42%
Never have shared needles (in last 30 days) NA 80%
Occasionally have shared needles (in last 30 days) NA 20%
Often or all the time shared needles (in last 30 days) NA 0%
doi:10.1371/journal.pone.0158641.t002
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differences in total lymphocyte count, frequency of CD14+ monocytes, or CD4+ T cells among
the groups (not shown) however IDUs had approximately 2-fold higher frequency of total B
cells, defined as CD19+ as compared to HCs (8.6% vs. 4.4%, p<0.005) (Fig 1A and 1B). This
observation was most pronounced in the CD19+CD20+ B cell population (7.2% vs 3.8%,
p<0.005), that is known to include nearly all peripheral blood B cell subsets. No significant dif-
ference was observed in the frequency of the CD19+CD20low/neg B cell population. The
CD19+CD20low/neg population is primarily described as being enriched for plasmablasts,
which are active antibody secreting cells, or pre-plasmablasts [37, 38]. A comprehensive phe-
notypic profiling of the B cell subsets (Fig 2) did not reveal significant phenotypic differences
within the CD19+CD20+ B cell population, although there was a notable 40% increase in IgD
+CD183(CXCR3)+ B cells among IDUs (p = 0.0935), suggesting there may be a low-level
chronic inflammatory phenotype in IDUs [39–41].
Fig 1. Increased total peripheral blood B cells in IDUs. PBMC were analyzed by flow cytometry. (A) Representative plots gated on live,
CD14-CD3-CD4- lymphocytes, the gate is colored red to highlight the expanded CD19+CD20+ total B cell population in IDUs. (B) Frequency of
CD19+ (live, CD14-CD3-CD4-) populations among lymphocytes defined by FSC and SSC, each symbol is an individual subject, the red lines
indicate mean. The singular CD19+ population is the combination of both the CD19+CD20low/neg population and the CD19+CD20+ population.
Flow cytometry was conducted once per sample.
doi:10.1371/journal.pone.0158641.g001
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Although the frequency of the CD19+CD20low/neg B cell population was not significantly
different between groups, numerous phenotypic differences were apparent within this popula-
tion. Within the CD19+CD20low/neg B cell population, IDUs exhibited a 30% increase in
CD21-CD27+ (p<0.05), 30% increase in IgD-CD27+ (p<0.05), with a reciprocal 50% decrease
in CD21-CD27- (p<0.005) and 40% decrease in IgD-CD27- (p<0.005), in addition to a 40%
increase in IgD-CD95+ (p<0.005) (Fig 2B and 2C). The CD19+CD20low/neg plasmablast
population has previously been defined by CD38 or CD138 expression [28, 38, 42], however,
no significant differences were observed between groups among CD19+CD20low/neg CD27
+CD38+ or CD138+ potential plasmablast populations (Fig 2A). The increased CD27 and
CD95 expression among the CD19+CD20low/neg is consistent with an activated B cell pheno-
type in IDUs.
Skewed plasma antibody profile among IDUs
Observing such prominent differences in the phenotype of the B cells in IDUs, we evaluated if
these alterations extended to the plasma antibody compartment. Comprehensive profiling of
plasma antibodies revealed gross differences between IDUs and HCs (Fig 3A). IDUs exhibited
significantly higher total IgM concentration (p<0.05), and although total IgG concentrations
were comparable between groups, IDUs had significantly higher IgG3 (p<0.005) and IgG4
(p<0.05) subclasses (Fig 3B). No significant difference in total IgA concentration was appar-
ent. This skewing of plasma antibody profiles suggests a higher frequency of subclinical infec-
tions or ongoing inflammation in IDUs [43].
No significant differences in the incidence of auto-reactive IgG antibody (anti-Sm, anti-
dsDNA) were observed (Fig 3A), suggesting that self-tolerance was being maintained in
IDUs. Several IDUs had increased HepC-specific IgG that may suggest previous exposure to
the virus. We next examined if there was any serum antibody reactivity to HIV; specifically
we did not observe any significant differences in anti-HIV p24 IgG or anti-HIV gp140 IgG
between the two groups; however, IDUs had significantly higher (p<0.05) HIV gp140 IgM
antibody titers (Fig 3C), which may suggest increased exposure to HIV within this popula-
tion, and may reflect a history of exposure that did not result in HIV infection. Only one
subject (IDU-23) exhibited anti-HIV p24 IgG and anti-HIV gp140 IgG antibody reactivities
that were substantially higher than the group of HCs, this subject also had numerous ele-
vated serum antibodies including anti-HepC IgG, -LPS IgG, -Sm IgG, and -dsDNA IgG,
which could indicate undiagnosed HIV infection or high levels of poly-reactive serum
antibodies.
Increased systemic inflammatory mediators in IDUs
To assess potential systemic alterations in innate immune mediators, an extensive panel of
plasma cytokines, chemokines and soluble factors was measured (Fig 4). The group of IDUs
had significantly increased plasma TGF-α (~10-fold, p<0.005; an EGFR ligand), TNF-α
(~5-fold, p<0.005; a potent inflammatory cytokine); IL-8 (~10-fold, p<0.001; a chemokine
important for neutrophil migration, induction of phagocytosis and angiogeneisis), and
sCD40L (~5-fold, p<0.0005; a potent inflammatory mediator produced primarily by platelets,
which induces proliferation and class-switching of B cells [44]) (Fig 4B). We also found
increased levels of plasma LPS (endotoxin) evident in several IDUs (p<0.01) (Fig 4A), sugges-
tive of bacterial infection or increased gut permeability [45, 46]. These results are consistent
with a chronic systemic inflammatory phenotype in IDUs.
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Fig 2. B cell phenotypic profile. (A) B cell profiles for live, CD14-CD3-CD4- CD19+CD20low/neg (left) and
CD19+CD20+ (right). Heat maps show data corresponding to a particular B cell subset (column) and subject
Humoral Alterations and Inflammation in Heroin Users
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(row). Colors correspond to z-scores computed separately for each subset using the mean and standard
deviation of the HCs. Both subsets and subjects were clustered hierarchically based on Euclidean distance
and complete linkage, although HCs and IDUs were clustered separately. Sample ID, gender (F = magenta,
M = blue) and race (W = white, B = black, A = Asian, AI = American Indian,— = unknown) are shown just to
the right of each heat map. Cocaine and heroin usage is shown as a bar graph to the right of the injection drug
user sample heat maps. Bar plot below each heat map shows the mean z-score for each subset for the IDUs
samples only (z-score based on mean, standard deviation of HCs only). Gray traces represent data from
individual IDU samples. (B) Representative plots gated on live, CD14-CD3-CD4- CD19+CD20low/neg or
CD19+CD20+ B cell populations, the gates are colored red to highlight expanded CD19+CD20low/neg CD27
+ subsets in IDUs. (C) Frequency of select CD19+CD20low/neg subsets, each symbol represents an
individual subject, the red lines indicates mean.
doi:10.1371/journal.pone.0158641.g002
Fig 3. Plasma antibody profile. Relative concentrations of plasma antibody species was determined by ELISAs. (A) Antibody profiles are shown as a
heat maps similar to Fig 1. Antibody concentrations were log-transformed prior to computing z-scores. (B) Plasma concentrations of total antibody
isotypes and IgG subclasses and (C) select antigen-specific antibodies. Each symbol represents an individual subject, the red lines indicate mean.
doi:10.1371/journal.pone.0158641.g003
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Altered ceramide profile in IDUs
Ceramides are bioactive lipids present in the circulation as components of lipoprotein com-
plexes and exosomes [47–50]. This class of sphingolipid regulates intra- and intercellular sig-
naling associated with inflammation, cellular growth, proliferation, differentiation, senescence,
and apoptosis [51]. At low levels, ceramides are important for injury-induced cytokine produc-
tion and for activating protein phosphatases and kinases involved in stress-related signaling
cascades [51]. However, at high levels, ceramides inhibit cell division and induce cellular dys-
function and apoptosis. Ceramide metabolism is both impacted by, and contributes to inflam-
mation [52, 53]. We measured plasma levels of simple and complex ceramides and found
considerable up-regulation of numerous ceramide species in the IDUs (Fig 5A) that included
significant increases of ceramide d18:1/16:0 (p<0.005), monohexosylceramide 18.1/16.0
(p<0.001), dihydroceramide d18:0/22:0 (p<0.005), and lactosylceramide d18:1/22:0 (p<0.005)
(Fig 5B) consistent with inflammation in IDUs.
Machine learning identifies major distinguishing features of IDUs
To distill the features that best distinguish IDUs from HCs, a machine learning multivariate
analysis approach was utilized that incorporated all measured features including cell phenotyp-
ing, plasma antibody, plasma cytokine/chemokine/factor, and plasma ceramide profiling data.
A supervised recursive feature elimination approach was utilized to identify the top ten features
that when combined, classified the samples as IDU or HC with 100% accuracy using 10-fold
Fig 4. Plasma analyte profile. Plasma cytokines, chemokines and growth factors were measured by Milliplex Immunoassay and LPS was measured by
a limulus assay. (A) Analyte profiles are shown as a heat map similar to above. Analyte concentrations were log-transformed prior to computing z-
scores. (B) Select plots of individual analytes, each symbol represents an individual subject, the red lines indicate mean.
doi:10.1371/journal.pone.0158641.g004
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 11 / 21
cross-validation (Table 3). IDUs were classified as having increased CD19+CD20+ B cells,
MIP1-β, sCD40L, TGF-α, TNF-α, anti-HIV gp140-specific IgM, total IgG4, MHC d18.1/16:0,
and MHC d18.1/22:0 with decreased IgD-CD27-CD19+CD20low/neg cells as compared to
HCs. Principal components analysis that considered only these ten selected features completely
Fig 5. Plasma ceramide profile. Plasma ceramide species were measured by LC/ESI/MS/MS analysis. (A) Ceramide profiles are shown as a
heat map similar to above. Ceramide concentrations were log-transformed prior to computing z-scores. Ceramide profile elements (columns)
were not clustered. (B) Select plots of individual ceramide species, each symbol represents an individual subject, red lines indicate mean.
doi:10.1371/journal.pone.0158641.g005
Table 3. Features Identified by Machine Learning Analysis.
Ranked using SVM weights Feature HC (mean) IDU (mean) P (univariate)
1 sCD40L (pg/ml) 120.2 249.5 0.0004
2 IgG4 (RU) 192.7 308.6 0.0310
3 CD19+CD20+ (% of lymphocytes) 3.8 7.2 0.0036
4 TGF-α (pg/ml) 0.8 1.4 0.0056
5 TNF-α (pg/ml) 2.6 4.1 0.0016
6 MIP-1β (pg/ml) 4.4 13.2 0.0330
7 IgD-CD27- (% of 19+20low) 48.0 27.6 0.0015
8 MonoHex Ceramide d18.1/16:0 (ng/ml) 0.04 0.07 <0.0001
9 gp140_IgM (RU) 634.9 1055.0 0.0529
10 MonoHex Ceramide d18:1/22:0 (ng/ml) 0.01 0.012 0.0269
doi:10.1371/journal.pone.0158641.t003
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segregated samples as either IDU or HC (Fig 6). These results demonstrate the breadth of sys-
temic alterations present in IDUs, and resolve a core set of features that may be of value to
monitor in future investigations of IDUs.
Discussion
Our comprehensive humoral-centric immunological profiling study revealed dramatic dysre-
gulation in active heroin IDUs. This was apparent at the gross level as increased total B cells
and total plasma IgM in the IDUs, and finer analysis revealed altered B cell phenoytpes; most
prominent within the minor CD19+CD20low/neg compartment with increased CD27+ and
CD95+ subsets, and increased plasma IgG3 and IgG4 subclasses in IDUs. Together, these dif-
ferences suggest greater immune activation at steady state in IDUs, a conclusion that is sup-
ported by significant increases in numerous plasma inflammatory mediators including
sCD40L and TNF-α. The underlying factors driving inflammation in IDUs are uncertain and
warrant further investigation.
Increased inflammation in IDUs could be a consequence of numerous factors. Opioids have
primarily been associated with decreased immune activation in studies of acute treatment and
cessation of use, however increased plasma IL-1β, IL-6, IL-8, IL-10, and TNF-α were observed
in heroin addicts undergoing methadone treatment as compared to healthy controls [16]. It
has been postulated by others that in the setting of chronic opioid use, lymphocytes and other
cell types may no longer be sensitive to opioids or perhaps could be hyper-responsive to
Fig 6. Principal component analysis of features identified bymachine learning pipeline. Principal
component analysis (PCA) of 19 HCs (black circles) and 19 IDUs (red asterisks) based on ten features from
the various assays identified by machine learning (CD19+CD20low/negIgD-CD27-, MIP-1β, gp140 IgM,
IgG4, CD19+CD20+, sCD40L, TGF-α, MH: d18:1/16:0, TNF-α and MH: d18:1/22:0). PCA was computed on
per-feature z-scores (based on all 38 samples) of log transformed data (except for B cell subset frequencies
which were not log-transformed).
doi:10.1371/journal.pone.0158641.g006
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opioids as a result of altered mu receptor expression and signaling [54, 55]. The majority (89%)
of our cohort of IDUs reported frequent cocaine use, which has been associated with increased
immune activation and inflammation in several studies [56–59]. The concomitant use of both
heroin and cocaine among IDUs, drugs that have been reported to have grossly opposite
immunological impacts, highlights the necessity of directly assessing this complex population.
In studies by Tomescu et al. [18, 60], increased inflammation, including NK cell activation,
plasma IP-10, and dendritic cell maturation were reported in IDUs, although mostly confined
to needle-sharing IDUs and not significantly elevated in non-sharing IDUs, suggesting that
inflammation may be driven by factors associated with the sharing of needles, such as increased
exposure to blood-borne pathogens or allo-antigens. Our findings of increased inflammation
in non-needle sharing IDUs do not necessarily contradict those of Tomescu et al. Perceived dif-
ferences may be a result of our larger sample size and non-identical outcome measures, and
together suggest that the immune dysregulation, such as increased total B cells and skewed
plasma IgG subclasses we observed, may be further exacerbated in needle-sharing IDUs.
The detection of LPS in the plasma of several IDUs suggests increased bacterial exposure.
This is consistent with increased bacterial infections, including sepsis, in IDUs [45], and may
contribute to TLR-driven inflammation. Increased plasma LPS is commonly observed in HIV-
infected patients and high-risk subjects, and has frequently been associated with, and suggested
to contribute to increased systemic inflammation [61–65]. Plasma LPS in HIV-infected
patients is suggested to be a consequence of microbial translocation, and is further elevated in
HIV+ IDUs compared to HIV+ non-IDUs [46]. Thus, we speculate that increased LPS in our
IDUs cohort may be the consequence of both exogenous bacterial exposure and microbial
translocation.
Recent advances in lipidomics have begun to reveal disease, aging, and infection associated
alterations in ceramides. Increased plasma ceramides have been associated with coronary
artery disease, alcohol abuse, chronic kidney disease, diabetes, HIV-Associated Neurocognitive
Disease, Alzheimer’s disease Parkinson’s disease, and depression [32, 66–73]. Elevated plasma
ceramide in IDUs highlights potential intersections of injection drug use with declines in physi-
ological and cognitive function [4, 74–80], although these associations were not directly tested
in this study. Likewise, it is unclear if ceramides can directly impact the function of B cells, and
these observations warrant further investigation. Interestingly, ceramides can facilitate viral
entry, including HIV attachment, and the particular ceramide composition of virions generated
by budding through the cell membrane can impact viral function [81], suggesting that up-regu-
lation of ceramides may facilitate viral infections in IDUs.
The up-regulation of inflammatory mediators in IDUs likely act directly on their B cells; for
example sCD40L and TNF-αmay drive B cell expansion, perhaps in a polyclonal fashion [82],
but may also exacerbate responses to insulting antigens (e.g. drug contaminants, allo-antigens,
microbes) contributing to IgG3 and IgG4 skewing. This process may be amplified by indirect
actions of TNF-α and IL-8 on accessory cells that shape the B cell response, such as T cells,
antigen presenting cells, and neutrophils. Despite the remarkable 2-fold expansion of CD19
+CD20+ B cells in IDUs, substantial phenotypic differences were not apparent, with the excep-
tion of increased IgD+CD183(CXCR3)+ in IDUs. CXCR3 expression on B cells has been sug-
gested to indicate migration to sites of inflammation [39, 40], and increased CXCR3+ B cells
have been observed in patients with chronic inflammation, including those with rheumatoid
arthritis and systemic lupus erythematous [41], indicating their increase in IDUs is consistent
with an increased inflammatory state. The CD19+CD20low/neg compartment appears to be
most sensitive to the increased inflammatory state of the IDUs, perhaps in-part driven by its
relative small abundance (~0.5% of PBMC). This B cell compartment and its subsets including
the CD19+CD20low/negCD27+ cells which are increased in IDUs, should be evaluated further
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for antibody secretion to determine if they are functionally pre-plasmablasts that have been
described previously in other contexts [37, 75, 83, 84]. Additionally, immunoglobulin reper-
toire analysis may reveal the extent to which B cell alterations in IDUs are a function of anti-
gen-driven or antigen-independent (e.g. TLR) expansion. The limited scope of our study did
not directly address whether injection drug use alters the functions of B cells, such as their abil-
ity to proliferate, differentiate, or produce cytokines in response to stimulation. However,
chronic inflammation may drive an exhausted-like immune response similar to that observed
in chronic infections [85, 86], or conversely hyper-responsiveness, similar to what we observed
in early-stage rheumatoid arthritis patients [28]. Both scenarios are likely to impact the charac-
teristics and efficacy of the B cell response to pathogens and vaccines in IDUs.
HIV is a major infectious disease threat for IDUs, and the substantial B cell alterations we
have observed in IDUs suggest they could have qualitatively distinct responses to HIV vaccine
candidates, potentially compromising the efficacy of future HIV vaccine strategies in this popu-
lation. The rigorous comparison by Yates et al. [26] of VAX003, the largest HIV vaccine effi-
cacy trial conducted thus far in IDUs to RV144, which was conducted in predominantly low-
risk subjects, may be the most compelling yet underappreciated example of how IDUs may
generate qualitatively distinct HIV vaccine responses. Both trials utilized the same AIDSVAX
gp120 protein immunogen, although RV144 included a canarypox prime (ALVAC) and
VAX003 only repetitive AIDSVAX immunizations. Yates et al. [26] examined the V1V2-speci-
fic IgG3 response rate, which correlated with a decreased risk of infection in RV144. RV144
participants had a higher response rate than VAX003 recipients (~60% vs ~20%-40%), how-
ever, those who did respond in VAX003 had a significantly higher magnitude of response than
the RV144 responders [26]. Also,>90% of VAX003 participants had a gp120-specific IgG4
response, in contrast to<20% of RV144 participants, which was suggested to be a consequence
of the two additional AIDSVAX boosts that the VAX003 participants received [26]. In light of
our findings of significantly higher total IgG3 and IgG4 in IDUs, another non-exclusive and
complementary interpretation is that IDUs have a greater predisposition to generate vaccine-
specific IgG3 and IgG4 responses, which we are actively investigating. A major detriment to
exacerbated IgG3 and IgG4 responses is the short half-life of IgG3 and the inability of IgG4 to
activate complement [43], which could dramatically impact the durability and functional activ-
ity of the humoral response, and may be a potential contributor to the increase in re-occurring
infections observed among IDUs.
A common concern for detailed immune profiling studies on limited numbers of samples,
such as ours is the extent to which false discovery or multiple outcomes can potentially accen-
tuate biological features that are actually random and not authentic differences between
groups. Our combined use of conventional univariate analysis and multivariate machine learn-
ing analysis revealed both features that have been previously reported to be impacted by injec-
tion drug use and novel features not previously identified. A follow-up study focused on these
core features, that included both larger sample sizes and a longitudinal component would be
ideal to thoroughly ascertain their true modulation in IDUs.
The elevated systemic inflammation in IDUs that we observed is consistent with previous
studies [16, 17, 87–89], and may contribute to co-morbidities within this population. Chronic
inflammation is associated with cardiovascular disease, kidney disease, accelerated aging, and
neurodegenerative diseases, all of which are increased among IDUs [4, 74–79]. Although
underlying HIV or Hepatitis C infections may also contribute to systemic inflammation and
these co-morbidities, our results indicate that other factors may contribute. Not previously
well-appreciated was the extent of humoral dysregulation among IDUs. In addition to poten-
tially contributing to inflammation-mediated co-morbidities, the humoral alterations
described here may have significant consequences for the protection of IDUs from pathogens,
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including their ability to generate effective responses to vaccines. Investigations into the impact
of anti-inflammatory interventions in IDUs are warranted, and may yield broad health benefits
for this growing population.
Supporting Information
S1 File. SVM Features. List of features used in SVM analysis.
(XLSX)
S2 File. Data. Contains study data.
(XLSX)
Acknowledgments
We would like to acknowledge the Rochester Victory Alliance, particularly the staff including
Susan Antenozzi, William Coughlin, Christopher Foote, Cody Gardner, and Andrew Moran.
We are grateful for the assistance of the University of Rochester Flow Cytometry Core Facility
and the staff and clients of the Trillium Health Syringe Exchange Program. We are most grate-
ful for the participation of the study volunteers.
Author Contributions
Conceived and designed the experiments: MSP MS BC CBMK SBM DMNHWVMCK JJK.
Performed the experiments: MSP MS BZ BC NH JJK. Analyzed the data: MSP MS BC AAK JT
AFR NH JJK. Contributed reagents/materials/analysis tools: DM AAK JT CF AFRWVMCK.
Wrote the paper: MSP AFR JT NH JJK.
References
1. Rudd RA, Paulozzi LJ, Bauer MJ, Burleson RW, Carlson RE, Dao D, et al. Increases in heroin overdose
deaths—28 States, 2010 to 2012. MMWRMorb Mortal Wkly Rep. 2014; 63(39):849–54. PMID:
25275328.
2. Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the
United States. N Engl J Med. 2015; 372(16):1573–4. doi: 10.1056/NEJMc1501822 PMID: 25875268.
3. Fugelstad A, Annell A, Agren G. Long-term mortality and causes of death among hospitalized Swedish
drug users. Scand J Public Health. 2014; 42(4):364–9. doi: 10.1177/1403494814525006 PMID:
24608092.
4. Buettner M, Toennes SW, Buettner S, Bickel M, Allwinn R, Geiger H, et al. Nephropathy in illicit drug
abusers: a postmortem analysis. Am J Kidney Dis. 2014; 63(6):945–53. doi: 10.1053/j.ajkd.2014.01.
428 PMID: 24823296.
5. Dettmeyer R, Friedrich K, Schmidt P, Madea B. Heroin-associated myocardial damages—conventional
and immunohistochemical investigations. Forensic Sci Int. 2009; 187(1–3):42–6. doi: 10.1016/j.
forsciint.2009.02.014 PMID: 19304418.
6. Lavender TW, McCarron B. Acute infections in intravenous drug users. Clin Med (Lond). 2013; 13
(5):511–3. doi: 10.7861/clinmedicine.13-5-511 PMID: 24115713.
7. Gonzales y Tucker RD, Frazee B. View from the front lines: an emergency medicine perspective on
clostridial infections in injection drug users. Anaerobe. 2014; 30:108–15. doi: 10.1016/j.anaerobe.2014.
09.005 PMID: 25230330.
8. Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, et al. Risk factors for skin and soft-
tissue abscesses among injection drug users: a case-control study. Clin Infect Dis. 2001; 33(1):35–40.
doi: 10.1086/320879 PMID: 11389492.
9. Kaushik KS, Kapila K, Praharaj AK. Shooting up: the interface of microbial infections and drug abuse. J
Med Microbiol. 2011; 60(Pt 4):408–22. doi: 10.1099/jmm.0.027540–0 PMID: 21389334.
10. Sacerdote P, Franchi S, Gerra G, Leccese V, Panerai AE, Somaini L. Buprenorphine and methadone
maintenance treatment of heroin addicts preserves immune function. Brain Behav Immun. 2008; 22
(4):606–13. doi: 10.1016/j.bbi.2007.12.013 PMID: 18294814.
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 16 / 21
11. McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune
response. Drug Alcohol Depend. 2001; 62(2):111–23. PMID: 11245967.
12. Taub DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity of mu- and
kappa-selective opioid agonists. Proc Natl Acad Sci U S A. 1991; 88(2):360–4. PMID: 1846441;
PubMed Central PMCID: PMC50810.
13. Jamali A, Roostaee MH, Soleimanjahi H, Ghaderi Pakdel F, Bamdad T. DNA vaccine-encoded glyco-
protein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Comp
Immunol Microbiol Infect Dis. 2007; 30(2):71–80. doi: 10.1016/j.cimid.2006.10.002 PMID: 17126902.
14. MeachamMC, Rudolph AE, Strathdee SA, Rusch ML, Brouwer KC, Patterson TL, et al. Polydrug Use
and HIV Risk Among People Who Inject Heroin in Tijuana, Mexico: A Latent Class Analysis. Subst Use
Misuse. 2015; 50(10):1351–9. doi: 10.3109/10826084.2015.1013132 PMID: 26444185.
15. Kuramoto SJ, Bohnert AS, Latkin CA. Understanding subtypes of inner-city drug users with a latent
class approach. Drug Alcohol Depend. 2011; 118(2–3):237–43. doi: 10.1016/j.drugalcdep.2011.03.
030 PMID: 21530105; PubMed Central PMCID: PMC3153580.
16. Chan YY, Yang SN, Lin JC, Chang JL, Lin JG, Lo WY. Inflammatory response in heroin addicts under-
going methadone maintenance treatment. Psychiatry Res. 2015; 226(1):230–4. doi: 10.1016/j.
psychres.2014.12.053 PMID: 25660662.
17. Chen SL, Lee SY, Tao PL, Chang YH, Chen SH, Chu CH, et al. Dextromethorphan attenuated inflam-
mation and combined opioid use in humans undergoing methadonemaintenance treatment. J Neu-
roimmune Pharmacol. 2012; 7(4):1025–33. doi: 10.1007/s11481-012-9400-1 PMID: 22990619.
18. Tomescu C, Duh FM, Lanier MA, Kapalko A, Mounzer KC, Martin MP, et al. Increased plasmacytoid
dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug
users. AIDS. 2010; 24(14):2151–60. doi: 10.1097/QAD.0b013e32833dfc20 PMID: 20647906; PubMed
Central PMCID: PMC3253656.
19. Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a system-
atic review. Lancet Infect Dis. 2007; 7(10):667–74. doi: 10.1016/S1473-3099(07)70237-2 PMID:
17897609.
20. Kamath GR, Shah DP, Hwang LY. Immune response to hepatitis B vaccination in drug using popula-
tions: a systematic review and meta-regression analysis. Vaccine. 2014; 32(20):2265–74. doi: 10.
1016/j.vaccine.2014.02.072 PMID: 24631093.
21. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. Immune correlates of vaccine
protection against HIV-1 acquisition. Sci Transl Med. 2015; 7(310):310rv7. doi: 10.1126/scitranslmed.
aac7732 PMID: 26491081.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209–20.
doi: 10.1056/NEJMoa0908492 PMID: 19843557.
23. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk
behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and
AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012; 12
(7):531–7. doi: 10.1016/S1473-3099(12)70088-9 PMID: 22652344; PubMed Central PMCID:
PMCPMC3530398.
24. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, dou-
ble-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine
among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194(12):1661–71. doi: 10.1086/
508748 PMID: 17109337.
25. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3
trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191
(5):654–65. doi: 10.1086/428404 PMID: 15688278.
26. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, WilliamsWT, et al. Vaccine-induced Env V1-
V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med.
2014; 6(228):228ra39. doi: 10.1126/scitranslmed.3007730 PMID: 24648342; PubMed Central PMCID:
PMCPMC4116665.
27. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture
(REDCap)—a metadata-driven methodology and workflow process for providing translational research
informatics support. J Biomed Inform. 2009; 42(2):377–81. doi: 10.1016/j.jbi.2008.08.010 PMID:
18929686; PubMed Central PMCID: PMCPMC2700030.
28. Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, et al. Decreased influenza-specific B
cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther.
2011; 13(6):R209. doi: 10.1186/ar3542 PMID: 22177419; PubMed Central PMCID:
PMCPMC3334662.
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 17 / 21
29. Kobie JJ, Alcena DC, Zheng B, Bryk P, Mattiacio JL, Brewer M, et al. 9G4 autoreactivity is increased in
HIV-infected patients and correlates with HIV broadly neutralizing serum activity. PLoS One. 2012; 7
(4):e35356. doi: 10.1371/journal.pone.0035356 PMID: 22530008; PubMed Central PMCID:
PMCPMC3329433.
30. Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, Izmailova ES, et al. Erroneous augmentation of
multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by
serum rheumatoid factor. Arthritis Rheum. 2011; 63(4):894–903. doi: 10.1002/art.30213 PMID:
21305505.
31. Bandaru VVR, Mielke M. M., Sacktor N., McArthur J.C., Grant I., Letendre S., Chang L., Wojna V.,
Pardo C., Calabresi P., Munsaka S., Haughey N.J. A lipid storage-like disorder contributes to cognitive
decline in HIV-infected subjects. Neurology. 2013;In press.
32. Mielke MM, Bandaru VV, Han D, An Y, Resnick SM, Ferrucci L, et al. Demographic and clinical vari-
ables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species. Aging
cell. 2015. doi: 10.1111/acel.12369 PMID: 26193443.
33. Guyon I, Elisseeff. An introduction to variable and feature selection. J Mach Learn Res. 2003; 3:1157–
82.
34. Kohavi R, John G. Wrappers for feature subset selection. Artif Intell. 1997; 97:273–324.
35. Guyon I, Weston J., Barnhill S., Vapnik V. Gene selection for cancer classification using support vector
machines. Mach Learn. 2002; 46:389–422.
36. Hidalgo-Munoz AR, Ramirez J, Gorriz JM, Padilla P. Regions of interest computed by SVMwrapped
method for Alzheimer's disease examination from segmented MRI. Front Aging Neurosci. 2014; 6:20.
doi: 10.3389/fnagi.2014.00020 PMID: 24634656; PubMed Central PMCID: PMCPMC3929832.
37. Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Reme T, et al. Characterization of a transitional pre-
plasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011;
187(8):3931–41. doi: 10.4049/jimmunol.1101230 PMID: 21918187.
38. Fink K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol.
2012; 3:78. doi: 10.3389/fimmu.2012.00078 PMID: 22566959; PubMed Central PMCID:
PMCPMC3341968.
39. Serre K, Cunningham AF, Coughlan RE, Lino AC, Rot A, Hub E, et al. CD8 T cells induce T-bet-depen-
dent migration toward CXCR3 ligands by differentiated B cells produced during responses to alum-pro-
tein vaccines. Blood. 2012; 120(23):4552–9. doi: 10.1182/blood-2012-03-417733 PMID: 23065152.
40. Liu RX, Wei Y, Zeng QH, Chan KW, Xiao X, Zhao XY, et al. Chemokine (C-X-C motif) receptor 3-posi-
tive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepa-
tocellular carcinoma. Hepatology. 2015; 62(6):1779–90. doi: 10.1002/hep.28020 PMID: 26235097.
41. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine receptors on
peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus.
Arthritis Res Ther. 2005; 7(5):R1001–13. doi: 10.1186/ar1776 PMID: 16207316; PubMed Central
PMCID: PMCPMC1257429.
42. Kaminski DA, Wei C, Qian Y, Rosenberg AF, Sanz I. Advances in human B cell phenotypic profiling.
Front Immunol. 2012; 3:302. doi: 10.3389/fimmu.2012.00302 PMID: 23087687; PubMed Central
PMCID: PMCPMC3467643.
43. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions.
Front Immunol. 2014; 5:520. doi: 10.3389/fimmu.2014.00520 PMID: 25368619; PubMed Central
PMCID: PMCPMC4202688.
44. Davidson DC, Jackson JW, Maggirwar SB. Targeting platelet-derived soluble CD40 ligand: a new treat-
ment strategy for HIV-associated neuroinflammation? J Neuroinflammation. 2013; 10:144. doi: 10.
1186/1742-2094-10-144 PMID: 24289660; PubMed Central PMCID: PMCPMC3906985.
45. Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N, et al. Prevalences and correlates of non-viral
injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug
Alcohol Depend. 2009; 100(1–2):9–16. doi: 10.1016/j.drugalcdep.2008.08.016 PMID: 19013725.
46. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, et al. Microbial translocation is asso-
ciated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008; 3(6):
e2516. doi: 10.1371/journal.pone.0002516 PMID: 18575590; PubMed Central PMCID:
PMCPMC2424175.
47. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin
Invest. 2011; 121(11):4222–30. doi: 10.1172/JCI57144 PMID: 22045572; PubMed Central PMCID:
PMCPMC3204836.
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 18 / 21
48. Kakazu E, Mauer AS, Yin M, Malhi H. Hepatocytes Release Ceramide-enriched Proinflammatory Extra-
cellular Vesicles in an IRE1alpha-dependent Manner. J Lipid Res. 2015. doi: 10.1194/jlr.M063412
PMID: 26621917; PubMed Central PMCID: PMCPMC4727419.
49. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, et al. Blood sphingolipi-
domics in healthy humans: impact of sample collection methodology. J Lipid Res. 2010; 51(10):3074–
87. doi: 10.1194/jlr.D008532 PMID: 20660127; PubMed Central PMCID: PMCPMC2936747.
50. Goldkorn T, Chung S, Filosto S. Lung cancer and lung injury: the dual role of ceramide. Handb Exp
Pharmacol. 2013;(216: ):93–113. doi: 10.1007/978-3-7091-1511-4_5 PMID: 23563653; PubMed Cen-
tral PMCID: PMCPMC4370279.
51. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996; 274
(5294):1855–9. PMID: 8943189.
52. Rivera IG, Ordonez M, Presa N, Gomez-Larrauri A, Simon J, Trueba M, et al. Sphingomyelinase D/cer-
amide 1-phosphate in cell survival and inflammation. Toxins (Basel). 2015; 7(5):1457–66. doi: 10.3390/
toxins7051457 PMID: 25938271; PubMed Central PMCID: PMCPMC4448157.
53. Hernandez-Corbacho MJ, Canals D, Adada MM, Liu M, Senkal CE, Yi JK, et al. Tumor Necrosis Fac-
tor-alpha (TNFalpha)-induced Ceramide Generation via Ceramide Synthases Regulates Loss of Focal
Adhesion Kinase (FAK) and Programmed Cell Death. J Biol Chem. 2015; 290(42):25356–73. doi: 10.
1074/jbc.M115.658658 PMID: 26318452; PubMed Central PMCID: PMCPMC4646185.
54. Regan PM, Dave RS, Datta PK, Khalili K. Epigenetics of micro-opioid receptors: intersection with HIV-1
infection of the central nervous system. J Cell Physiol. 2012; 227(7):2832–41. doi: 10.1002/jcp.24004
PMID: 22034138; PubMed Central PMCID: PMCPMC3971722.
55. Toskulkao T, Pornchai R, Akkarapatumwong V, Vatanatunyakum S, Govitrapong P. Alteration of lym-
phocyte opioid receptors in methadone maintenance subjects. Neurochem Int. 2010; 56(2):285–90.
doi: 10.1016/j.neuint.2009.10.013 PMID: 19913582.
56. Kiebala M, Singh MV, Piepenbrink MS, Qiu X, Kobie JJ, Maggirwar SB. Platelet Activation in Human
Immunodeficiency Virus Type-1 Patients Is Not Altered with Cocaine Abuse. PLoS One. 2015; 10(6):
e0130061. doi: 10.1371/journal.pone.0130061 PMID: 26076359; PubMed Central PMCID:
PMCPMC4467977.
57. Narvaez JC, Magalhaes PV, Fries GR, Colpo GD, Czepielewski LS, Vianna P, et al. Peripheral toxicity
in crack cocaine use disorders. Neurosci Lett. 2013; 544:80–4. doi: 10.1016/j.neulet.2013.03.045
PMID: 23597759.
58. Pereira J, Saez CG, Pallavicini J, Panes O, Pereira-Flores K, Cabreras MJ, et al. Platelet activation in
chronic cocaine users: effect of short term abstinence. Platelets. 2011; 22(8):596–601. doi: 10.3109/
09537104.2011.578181 PMID: 21806491.
59. Bagasra O, Forman L. Functional analysis of lymphocytes subpopulations in experimental cocaine
abuse. I. Dose-dependent activation of lymphocyte subsets. Clin Exp Immunol. 1989; 77(2):289–93.
PMID: 2528433; PubMed Central PMCID: PMCPMC1541992.
60. Tomescu C, Seaton KE, Smith P, Taylor M, Tomaras GD, Metzger DS, et al. Innate activation of MDC
and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when com-
pared with low-risk nonsharing IV-drug user controls. J Acquir Immune Defic Syndr. 2015; 68(3):264–
73. doi: 10.1097/QAI.0000000000000470 PMID: 25514793; PubMed Central PMCID: PMC4329050.
61. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a
cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365–71. doi: 10.
1038/nm1511 PMID: 17115046.
62. Wallet MA, Rodriguez CA, Yin L, Saporta S, Chinratanapisit S, HouW, et al. Microbial translocation
induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following ther-
apy. AIDS. 2010; 24(9):1281–90. doi: 10.1097/QAD.0b013e328339e228 PMID: 20559035; PubMed
Central PMCID: PMCPMC2888494.
63. JiangW, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA
correlate with immune activation and the magnitude of immune restoration in persons with antiretrovi-
ral-treated HIV infection. J Infect Dis. 2009; 199(8):1177–85. doi: 10.1086/597476 PMID: 19265479;
PubMed Central PMCID: PMCPMC2728622.
64. Vassallo M, Mercie P, Cottalorda J, Ticchioni M, Dellamonica P. The role of lipopolysaccharide as a
marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J. 2012;
9:174. doi: 10.1186/1743-422X-9-174 PMID: 22925532; PubMed Central PMCID: PMCPMC3495848.
65. Palmer CD, Tomassilli J, Sirignano M, Romero-Tejeda M, Arnold KB, Che D, et al. Enhanced immune
activation linked to endotoxemia in HIV-1 seronegative MSM. AIDS. 2014; 28(14):2162–6. doi: 10.
1097/QAD.0000000000000386 PMID: 25003719; PubMed Central PMCID: PMCPMC4460793.
66. Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, et al. Plasma concentra-
tions of molecular lipid species in relation to coronary plaque characteristics and cardiovascular
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 19 / 21
outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis. 2015; 243(2):560–6. doi: 10.
1016/j.atherosclerosis.2015.10.022 PMID: 26523994.
67. Reichel M, Honig S, Liebisch G, Luth A, Kleuser B, Gulbins E, et al. Alterations of plasma glyceropho-
spholipid and sphingolipid species in male alcohol-dependent patients. Biochim Biophys Acta. 2015;
1851(11):1501–10. doi: 10.1016/j.bbalip.2015.08.005 PMID: 26291032.
68. Bergman BC, Brozinick JT, Strauss A, Bacon S, Kerege A, Bui HH, et al. Serum sphingolipids: relation-
ships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab. 2015;
309(4):E398–408. doi: 10.1152/ajpendo.00134.2015 PMID: 26126684; PubMed Central PMCID:
PMCPMC4537923.
69. Larsen PJ, Tennagels N. On ceramides, other sphingolipids and impaired glucose homeostasis. Mol
Metab. 2014; 3(3):252–60. doi: 10.1016/j.molmet.2014.01.011 PMID: 24749054; PubMed Central
PMCID: PMCPMC3986510.
70. Mielke MM, Maetzler W, Haughey NJ, Bandaru VV, Savica R, Deuschle C, et al. Plasma ceramide and
glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive
impairment: a pilot study. PLoS One. 2013; 8(9):e73094. doi: 10.1371/journal.pone.0073094 PMID:
24058461; PubMed Central PMCID: PMC3776817.
71. Bandaru VV, Mielke MM, Sacktor N, McArthur JC, Grant I, Letendre S, et al. A lipid storage-like disorder
contributes to cognitive decline in HIV-infected subjects. Neurology. 2013; 81(17):1492–9. doi: 10.
1212/WNL.0b013e3182a9565e PMID: 24027056; PubMed Central PMCID: PMC3888167.
72. Gracia-Garcia P, Rao V, Haughey NJ, Ratnam Banduru VV, Smith G, Rosenberg PB, et al. Elevated
plasma ceramides in depression. The Journal of neuropsychiatry and clinical neurosciences. 2011; 23
(2):215–8. doi: 10.1176/appi.neuropsych.23.2.215 PMID: 21677254; PubMed Central PMCID:
PMC3121176.
73. Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E, Zaidi N, et al. Plasma Sphingomyelins
are Associated with Cognitive Progression in Alzheimer's Disease. J Alzheimers Dis. 2011. Epub 2011/
08/16. D327536MH4R6M204 [pii] doi: 10.3233/JAD-2011-110405 PMID: 21841258.
74. Machowska A, Carrero JJ, Lindholm B, Stenvinkel P. Therapeutics targeting persistent inflammation in
chronic kidney disease. Transl Res. 2016; 167(1):204–13. doi: 10.1016/j.trsl.2015.06.012 PMID:
26173187.
75. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative
tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple
myeloma. Cancer Cell. 2013; 24(3):289–304. doi: 10.1016/j.ccr.2013.08.009 PMID: 24029229;
PubMed Central PMCID: PMCPMC4118579.
76. Cheng GL, Zeng H, Leung MK, Zhang HJ, Lau BW, Liu YP, et al. Heroin abuse accelerates biological
aging: a novel insight from telomerase and brain imaging interaction. Transl Psychiatry. 2013; 3:e260.
doi: 10.1038/tp.2013.36 PMID: 23695235; PubMed Central PMCID: PMCPMC3669923.
77. Kovacs GG, Horvath MC, Majtenyi K, Lutz MI, Hurd YL, Keller E. Heroin abuse exaggerates age-
related deposition of hyperphosphorylated tau and p62-positive inclusions. Neurobiol Aging. 2015; 36
(11):3100–7. doi: 10.1016/j.neurobiolaging.2015.07.018 PMID: 26254956; PubMed Central PMCID:
PMCPMC4609594.
78. Anthony IC, Norrby KE, Dingwall T, Carnie FW, Millar T, Arango JC, et al. Predisposition to accelerated
Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
Brain. 2010; 133(Pt 12):3685–98. doi: 10.1093/brain/awq263 PMID: 21126996.
79. Reece AS, Hulse GK. Duration of opiate exposure as a determinant of arterial stiffness and vascular
age in male opiate dependence: a longitudinal study. J Clin Pharm Ther. 2014; 39(2):158–67. doi: 10.
1111/jcpt.12121 PMID: 24329809.
80. van Holst RJ, Schilt T. Drug-related decrease in neuropsychological functions of abstinent drug users.
Curr Drug Abuse Rev. 2011; 4(1):42–56. PMID: 21466500.
81. Schneider-Schaulies J, Schneider-Schaulies S. Sphingolipids in viral infection. Biol Chem. 2015; 396
(6–7):585–95. doi: 10.1515/hsz-2014-0273 PMID: 25525752.
82. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Chavarin P, Cogne M, Richard Y, et al. Human platelets
can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol. 2007;
35(9):1376–87. doi: 10.1016/j.exphem.2007.05.021 PMID: 17656005.
83. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for nonmalignant human plas-
mablasts. Blood. 2001; 97(6):1817–22. PMID: 11238125.
84. Kassambara A, Reme T, Jourdan M, Fest T, Hose D, Tarte K, et al. GenomicScape: an easy-to-use
web tool for gene expression data analysis. Application to investigate the molecular events in the differ-
entiation of B cells into plasma cells. PLoS Comput Biol. 2015; 11(1):e1004077. doi: 10.1371/journal.
pcbi.1004077 PMID: 25633866; PubMed Central PMCID: PMCPMC4310610.
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 20 / 21
85. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical
outcome in autoimmunity and infection. Nature. 2015; 523(7562):612–6. doi: 10.1038/nature14468
PMID: 26123020; PubMed Central PMCID: PMCPMC4623162.
86. Yao ZQ, Moorman JP. Immune exhaustion and immune senescence: two distinct pathways for HBV
vaccine failure during HCV and/or HIV infection. Arch Immunol Ther Exp (Warsz). 2013; 61(3):193–
201. doi: 10.1007/s00005-013-0219-0 PMID: 23400275; PubMed Central PMCID: PMCPMC3792483.
87. Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski ER, Chokshi S, et al. Cytokine profiles in
high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance
to hepatitis C virus infection. J Viral Hepat. 2012; 19(7):501–8. doi: 10.1111/j.1365-2893.2011.01574.x
PMID: 22676363.
88. Leng SX, Dandorf S, Li H, Carlson J, Hui J, Mehta SH, et al. Associations of Circulating Soluble Tumor
Necrosis Factor-alpha Receptors 1 and 2 with Interleukin-6 Levels in an Aging Cohort of Injection Drug
Users with or at High Risk for HIV Infection. AIDS Res HumRetroviruses. 2015; 31(12):1257–64. doi:
10.1089/AID.2015.0134 PMID: 26414536; PubMed Central PMCID: PMCPMC4663639.
89. Neri M, Panata L, Bacci M, Fiore C, Riezzo I, Turillazzi E, et al. Cytokines, chaperones and neuroinflam-
matory responses in heroin-related death: what can we learn from different patterns of cellular expres-
sion? Int J Mol Sci. 2013; 14(10):19831–45. doi: 10.3390/ijms141019831 PMID: 24084728; PubMed
Central PMCID: PMCPMC3821589.
Humoral Alterations and Inflammation in Heroin Users
PLOS ONE | DOI:10.1371/journal.pone.0158641 July 5, 2016 21 / 21
